Combination therapy for advanced stomach or gastroesophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread to other parts of the body.
- You have not had any prior systemic therapy (like chemotherapy or targeted drugs) for advanced disease.
- Your tumor must show certain markers (Claudin 18.2 and PD-L1) when tested in a lab.
- You need at least one measurable tumor on imaging scans.
- You should be in good physical condition (ECOG 0 or 1) and have a life expectancy of at least 3 months.
- You must not have HER2-positive cancer and must be free of active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial compares a shot under the skin versus an IV infusion of tislelizumab, given along with chemotherapy, for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the shot works as well as the IV and may be more convenient.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This trial tests a combination of chemotherapy, low-dose radiation, and an immunotherapy drug called tislelizumab for patients with stomach or gastroesophageal junction cancer that has not spread to distant organs. The goal is to see if this combination can shrink tumors and improve outcomes before and after surgery.
Hear when a new Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.